From: kristoff@GENBANK.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 33, pt. 1, 11 September 1992
Date: 15 Sep 92 18:56:44 GMT
Distribution: bionet


NOTE: The NIH Guide may be split into more than one mail message to
avoid truncation during e-mail distribution.  The first message always
begins with the RFP/RFA summary sections followed by the appended
texts of the full RFP/RFAs.
----------------------------------------------------------------------

$$XID NIHGUIDE 19920911 V21N33 P1O1 ************************************
X-comment: RFAs described: AG-93-01, CA/NR/92-27

NIH GUIDE - Vol. 21, No. 33 - September 11, 1992

$$INDEX BEGIN *******************************************************

                               NOTICES

$$INDEX N1 **********************************************************

NATIONAL HUMAN SUBJECT PROTECTIONS WORKSHOPS
National Institutes of Health
Food and Drug Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH; FOOD AND DRUG ADMINISTRATION

$$INDEX N2 **********************************************************

RESEARCH CAREER DEVELOPMENT AWARD PROGRAM FOR RE-ENTRY INTO THE
NEUROLOGICAL SCIENCES
National Institute of Neurological Disorders and Stroke
INDEX:  NEUROLOGICAL DISORDERS, STROKE

$$INDEX N3 **********************************************************

PUBLIC HEALTH SERVICE POLICY RELATING TO DISTRIBUTION OF UNIQUE
RESEARCH RESOURCES PRODUCED WITH PHS FUNDING
Public Health Service
INDEX:  PUBLIC HEALTH SERVICE

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$INDEX R1 **********************************************************

SYNTHESIS OF CHEMICAL MODIFIERS OF RADIATION RESPONSE (RFP NCI-CM-
37828-75)
National Cancer Institute
INDEX:  CANCER

$$INDEX R2 11/13/92 *************************************************

GENETIC AND MOLECULAR BASIS OF LONGEVITY (RFA AG-93-01)
National Institute on Aging
INDEX:  AGING

$$INDEX R3 01/19/93 *************************************************

QUALITY OF LIFE ASSESSMENT IN SPECIAL POPULATIONS (RFA CA/NR-92-27)
National Cancer Institute
National Center for Nursing Research
INDEX:  CANCER; NURSING RESEARCH

                               ERRATUM

$$INDEX E1 **********************************************************

CAREER DEVELOPMENT AWARDS FOR UNDERREPRESENTED MINORITY CLINICIAN-
INVESTIGATORS
National Institute of Diabetes and Digestive and Kidney Disorders
INDEX: DIABETES, DIGESTIVE, KIDNEY DISEASES

$$INDEX E2 ***********************************************************

WORKSHOP ON MINIMIZING PAIN AND DISTRESS IN LABORATORY ANIMALS
National Institutes of Health
INDEX:  NATIONAL INSTITUTES OF HEALTH

This publication is also available electronically to institutions via
BITNET or INTERNET.  Alternative access is through the NIH Grant Line
using a personal computer.  Contact Dr. John James at 301/496-7554 for
details, or send an E-mail message to ZNS@NIHCU.

THE NIH GUIDE WILL NOT BE PUBLISHED ON SEPTEMBER 18, 1992.  THE NEXT
ISSUE OF THE GUIDE WILL BE SEPTEMBER 25, 1992.

$$INDEX END *********************************************************

                               NOTICES

$$N1 BEGIN **********************************************************

NATIONAL HUMAN SUBJECT PROTECTIONS WORKSHOPS

NIH GUIDE, Volume 21, Number 33, September 11, 1992

P.T. 42; K.W. 0783005, 1014006

National Institutes of Health
Food and Drug Administration

The Office for Protection from Research Risks (OPRR) of the National
Institutes of Health (NIH) and the Food and Drug Administration (FDA)
are continuing to sponsor a series of workshops on responsibilities of
researchers, Institutional Review Boards (IRBs), and institutional
officials for the protection of human subjects in research. The
workshops are open to everyone with an interest in research involving
human subjects.  The meetings should be of special interest to those
persons currently serving or about to begin serving as a member of an
IRB.  Issues discussed at these workshops are relevant to all other
Public Health Service agencies.  The current schedule includes the
following:

SOUTHWESTERN WORKSHOP

DATES:  November 16 & 17, 1992

LOCATION:
Wyndham Warwick
5701 Main Street
Houston, TX  77005
Telephone:  (713) 526-1991

SPONSORS:
University of Texas Health Science Center at Houston
Prairie View A & M University

REGISTRATION:
Ms. Paula Knudson
Executive Coordinator
Office of Research Support Committee
University of Texas Health Science Center at Houston
P.O. Box 20036
Houston, TX  77225
Telephone:  (713) 792-5048

TITLE:  Geriatric Research as an Ethical Mandate:  Politics, Policy,
and Problems

DESCRIPTION: Expanded life expectancies and expanding technologies are
swelling the ranks of the frail and disabled elderly.  Minimal research
has been carried out to understand the problems this subject group and
their families encounter in finding solutions to their health and
social needs.  The conference will identify key problems that need to
be studied; isolate the risks and benefits associated with behavioral,
clinical, or evaluation research designed to enroll this group as
subjects; and pose solutions that will meet the needs of regulators,
scientists, and the elderly.

The program is designed to be of interest to physicians, nurses,
pharmacists, scientific investigators, other health care professionals,
clergy, lawyers, medical, nursing, social work students, and
psychologists as well as IRB members and administrators.  Attention
will be paid to Federal regulations with special emphasis on the
assessment of risks---medical, legal, and psychosocial.  Opportunities
will be available through workshops, question periods, and informal
discussions for participants to exchange ideas and interests with
faculty and OPRR and FDA representatives.

SOUTHEASTERN WORKSHOP

DATES:  January 14 & 15, 1993

LOCATION:
Sheraton Sand Key Resort
1160 Gulf Boulevard
Clearwater Beach, FL  33515
Telephone:  (813) 595-1611

SPONSORS:
University of South Florida
Florida A & M University

REGISTRATION:
Ms. Eileen Highsmith
Executive Secretary
University of South Florida
4202 E. Fowler Avenue (MP.FAO-126)
Tampa, FL  33620-7900
Telephone:  (813) 974-2897

TITLE:  Barriers to Informed Consent:  Language, Age Factors, Trauma,
and Women/Minority Issues

DESCRIPTION: Today's researchers face numerous barriers to obtaining an
informed consent.  Such issues as age, language, mental capacity, and
sobriety may affect the ability of subjects to give a truly informed
consent.  Many of these barriers oftentimes impact the pool of subjects
which an investigator is willing (or able) to use in a research
project.  In addition, recent legislation from the Congress was
designed to address the issue of inadequate numbers of women and
minorities in research projects.  This conference has been designed to
address three main areas in which barriers to informed consent may
exist:  mental competence, ethnic and gender issues, and research with
children and the elderly.

The conference program is designed to be of value to physicians,
nurses, pharmacists, scientific investigators, and other health care
professionals.  All IRB members, students in health care areas and
administrators will also benefit from the conference.  Attention will
be given to Federal regulations governing research on human subjects,
with special emphasis placed on the assessment of risks---medical,
legal, and psychosocial.  Ample opportunities will be provided to
exchange ideas and interests, through question and answer sessions and
informal discussions.

SOUTHWESTERN WORKSHOP

DATES:  February 12 & 13, 1993

LOCATION:
Sheraton Tempe Mission Palms Hotel
60 East 5th Street
Tempe, AZ  85281
Telephone:  (602) 894-1400

SPONSORS:
Arizona State University
Northern Arizona University

REGISTRATION:
Ms. Carol Jablonski
IRB Coordinator
Office of the Assistant Vice President for Research
Arizona State University
Tempe, AZ  85287-3403
Telephone:  (602) 965-6788

TITLE:  Contemporary Issues in Human Subject Research:  Challenges for
Today's IRBs

DESCRIPTION: This program is designed to be a practical working session
to explore contemporary issues in human subjects protection including
regulations and assurances, categorization of research protocols, uses
of special populations, experimental design and scientific merit, fetal
tissue research, ethical/legal issues in human subjects research, and
conflict of interest.  As appropriate, topics will be discussed from
the perspective of the clinical researcher and the behavioral/social
science researcher. Issues will be discussed in a panel format with
ample time for audience questions.  An outstanding faculty has been
assembled.

This program should be of interest to researchers in clinical medicine
and the behavioral and social sciences. Institutional Review Board
members, university and hospital administrators, lawyers, ethicists,
health care practitioners, students, and other persons with interests
in human subject protection issues.

For further information regarding these workshop or future NIH/FDA
National Human Subject Protections Workshops, please contact:

Ms. Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101

$$N1 END ************************************************************

$$N2 BEGIN **********************************************************

RESEARCH CAREER DEVELOPMENT AWARD PROGRAM FOR RE-ENTRY INTO THE
NEUROLOGICAL SCIENCES

NIH GUIDE, Volume 21, Number 33, September 11, 1992

P.T. 34; K.W. 1002030, 0785035

National Institute of Neurological Disorders and Stroke

The purpose of the National Institute of Neurological Disorders and
Stroke (NINDS) program for re-entry into the neurological sciences is
to assist basic and clinical neurological scientists to re-enter into
active careers in science and academic medicine related to the
neurological sciences.  The program is designed to provide the re-entry
opportunity to individuals who have experienced an interruption of
three to eight years in their careers.  It is a postdoctoral award
(K01) designed to support individuals who would have high potential for
careers as independent investigators in basic or clinical research in
the neurological sciences following a period of support that will allow
the individual to update his/her research skills.  These awards would
allow the individual to pursue a research project that would enable
him/her to update research skills, learn new techniques, and obtain any
other experience necessary.  This effort may be complemented by taking
courses appropriate to the research objectives of the award.  The award
provides salary for the awardee of up to $50,000 per year and a
research allowance of up to $20,000 per year.

To obtain a copy of the program guidelines, please contact:

Mr. Edward M. Donohue
Deputy Director
Division of Extramural Activities
National Institute of Neurological Disorders and Stroke
Bethesda, MD  20892
Telephone:  (301) 496-4188

$$N2 END ************************************************************

$$N3 BEGIN **********************************************************

PUBLIC HEALTH SERVICE POLICY RELATING TO DISTRIBUTION OF UNIQUE
RESEARCH RESOURCES PRODUCED WITH PHS FUNDING

NIH GUIDE, Volume 21, Number 33, September 11, 1992

P.T. 36; K.W. 0780010

Public Health Service

This announcement is a revision of the one last appearing in the NIH
Guide for Grants and Contracts on September 16, 1988, Vol. 17, No. 29,
pages 1 and 2.  This revised notice contains a number of changes in
policy that the agencies of the Public Health Service (PHS) have
determined should be implemented.

Investigators conducting biomedical research frequently develop unique
research resources.  Categories of these resources include:  synthetic
compounds, organisms, cell lines, viruses, cell products, cloned DNA,
as well as DNA sequences, mapping information, crystallographic
coordinates, and spectroscopic data.  Some specific examples are:
specialized and/or genetically defined cell lines, including normal and
diseased human cells; monoclonal antibodies; hybridoma cell lines;
microbial cells and products; viruses and viral products; recombinant
nucleic acid molecules; DNA probes; nucleic acid and protein sequences;
certain types of animals such as transgenic mice; and intellectual
property such as computer programs.  The PHS provides the following
statement of policy concerning unique research resources developed
through PHS awards.

A.  Policy on Distribution of Research Resources

The policy of the PHS is to make available to the public the results
and accomplishments of the activities that it funds. Restricted
availability of unique resources upon which further studies are
dependent can impede the advancement of research and the delivery of
medical care.  Therefore, when these resources are developed with PHS
funds and the associated research findings have been published or after
they have been provided to the agencies under contract, it is important
that they be made readily available for research purposes to qualified
individuals within the scientific community.  This policy applies to
PHS intramural investigators as well as extramural scientists funded by
PHS grants, cooperative agreements, and contracts.

Because of concern that some crystallographers are not making their
coordinates available promptly (see Science, Vol. 245, p. 1179), one of
the national advisory councils of the NIH and the executive committee
of another institute recently adopted resolutions affirming the policy
of the International Union of Crystallographers (IUCr) (Acta Cryst.,
A45: 658, 1989).  The PHS has now adopted the IUCr policy that includes
data from publications based on spectroscopic data such as nuclear
magnetic resonance as well as crystallographic coordinates.

The PHS encourages investigators who have such resources to consult the
appropriate Program Administrators who may be of assistance in
determining a suitable distribution mechanism. Such a mechanism should
take into consideration all applicable Federal regulations including,
but not limited to:  those regarding human subjects, animal welfare,
and use and handling of hazardous materials, where applicable.
Investigators requesting materials should provide evidence of having
the proper training, experience, and facilities to make use of the
items they request. Program staff of the agencies will be available to
assist in verification of credentials of requesters where such concern
exists on the part of suppliers.

Investigators who believe that they will be unable to implement this
policy should promptly contact the appropriate PHS Program
Administrator to discuss the circumstances, obtain information that
might facilitate compliance with the policy, and reach an understanding
in advance of the subsequent award.  For research and development
contracts, approval should be obtained from the PHS Contracting Officer
before distribution of unique resources, unless the terms of the
contract permit distribution without prior clearance of the Contracting
Officer.  In order to facilitate the availability of unique or novel
biological materials and resources developed with PHS funds,
investigators may distribute the materials through their own laboratory
or institution or submit them, if appropriate, to entities such as the
American Type Culture Collection or other repositories.  In the case of
unique biological information, such as DNA sequences or
crystallographic coordinates, investigators are expected to submit them
to the appropriate data banks because they otherwise are not truly
accessible to the scientific community.  When distributing unique
resources, investigators are to include pertinent information on the
nature, quality, or characterization of the materials.

Investigators must exercise great care to ensure that resources
involving human cells or tissues do not identify original donors or
subjects, directly or through identifiers, such as codes linked to the
donors or subjects.

The goals of some programs, (e.g., the Human Genome Program) are such
that applicants for certain projects may be required to provide plans
for the sharing of data and materials.  These plans will undergo review
by program staff and the national advisory council prior to award.

B.  Distribution Costs

Institutions and investigators may charge the requester, if necessary,
for the reasonable cost of production of unique biological materials,
and for packaging and shipping,  Such costs may include labor,
supplies, and other directly related expenses. Investigators should
note, however, that such a charge accrues as general program income.
This should not be an impediment to the distribution of materials, but
investigators and institutions are advised that:

a) for grants, the income is governed by 45 CFR Part 74 and it must be
reported on the Financial Status Report.  Questions regarding these
policies and the treatment of income should be directed to the Grants
Management Officer.

b) for contracts, the income is governed by Federal Acquisition
Regulations (FAR) 45.610-3.  Contracting Officers must be contacted
before generating any revenues from the distribution of materials.  Any
contract under which research resources would be sold require specific
contract instructions.  Existing contracts may require an amendment and
specific approval of the Contracting Officer to render them allowable.

C.  Inventions and Commercialization

Federal policy encourages the commercialization of the products of
research developed as a consequence of Federal funding; therefore, the
intent of this policy is to not discourage, impede, or prohibit the
organization that develops unique research resources or intellectual
property from commercializing the products.  Investigators may make
their materials available to others for commercial purposes with
appropriate restrictions and licensing terms as they and their
institution deem necessary.

Institutions are reminded that some of these products may be inventions
subject to the various laws and regulations applicable to patents and
must be reported to the Extramural Inventions Reports Office of the
NIH.  The terms for licensing of unpatented research products, such as
cell lines, monoclonal antibodies, and other materials and products,
should generally be no more restrictive than would have been the case
had they been patented---for example, only if there is full public
disclosure of the invention/discovery, availability through a
repository, and written agreement to end all fees and constraints after
17 years. When reporting is required, it should occur at the earliest
possible time.  (See 37 CFR 401 and NIH Guide for Grants and Contracts,
Vol. 19, No. 6, February 9, 1990, page 2).

$$N3 END ************************************************************

               NOTICES OF AVAILABILITY (RFPs AND RFAs)

$$R1 BEGIN NCI-CM-37828-75 ******************************************

SYNTHESIS OF CHEMICAL MODIFIERS OF RADIATION RESPONSE

NIH GUIDE, Volume 21, Number 33, September 11, 1992

RFP AVAILABLE: NCI-CM-37828-75

P.T. 34; K.W. 0745062, 1003006, 0755025

National Cancer Institute

The Radiotherapy Development Branch, Radiation Research Program,
Division of Cancer Treatment , National Cancer Institute is seeking
organizations with the capability to design, synthesize, and
characterize new and novel chemical modifiers of radiation response.
Classes of interest are:  bioreductive agents, agents that exploit
tumor pathophysiology, inhibitors of repair of radiation damage, and
free radical base agents.  The project requires designated data
obtained from in vitro testing of synthesized compounds and data
regarding the efficacy in vivo of designated compounds with significant
activity in vitro.

The offeror should include an experienced radiobiologist and an
experienced synthetic organic chemist on the project team, and the
Principal Investigator should possess a doctorate in a relevant
science.  In addition, the offeror must be AAALAC accredited or
equivalent and be capable of maintaining a conventional rodent colony
of at least 400 mice.  The offeror must also have radiation capability
suitable for irradiating mice and cell cultures.  Equipment for
physicochemical and pharmacological analysis (e.g., UV, IR, NMR, HPLC,
and polargraphic or pulse radiolysis for measuring electron affinity,
when appropriate) of compounds to be synthesized is also required.

RFP No. NCI-CM-37828-75 will be issued, upon written request to Bernice
Evans, Contract Specialist, on or about August 10, 1992, with a due
date for receipt of proposals on December 15, 1992.  It is anticipated
that an incrementally funded contract will be awarded for a period of
four years beginning on or about June 30, 1993.  This project is a
recompetition of the work being done under Contract No. NO1-CM-07321 by
Auckland UniService, Ltd., Auckland, New Zealand. (249)  No collect
calls will be accepted.

Copies of the RFP may be obtained by sending a written request to:

Ms. Bernice Evans
National Cancer Institute
Research Contracts Branch, TCS
Executive Plaza South, Room 603
Bethesda, MD  20892
Telephone:  (301) 496-8620

$$R1 END ************************************************************

$$R2 BEGIN AG-93-01 FULL-TEXT ***************************************

GENETIC AND MOLECULAR BASIS OF LONGEVITY

NIH GUIDE, Volume 21, Number 33, September 11, 1992

RFA AVAILABLE:  AG-93-01:

P.T. 34; K.W. 1002019, 0710010, 0760015, 1002008, 0710030

National Institute on Aging

Letter of Intent Receipt Date:  October 1, 1992
Application Receipt Date:  November 13, 1992

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The National Institute on Aging (NIA) invites applications for R01
grants to support basic research on the genetic and molecular bases of
longevity.  The goals of the Genetic and Molecular Basis of Longevity
RFA are to identify genes that promote longevity and delay the onset of
senescence, termed Longevity Assurance Genes (LAG), and determine the
biochemical functions and molecular mechanisms of action of these LAGs.
A multidisciplinary approach to these complex areas of basic research
will facilitate the application of genetic, biochemical and molecular
techniques to defining the genetic and molecular bases of longevity.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Genetic and Molecular Basis of Longevity, is related to the priority
area of aging. Delineation of the genetic and molecular bases of
longevity and senescence will lead to a fundamental understanding of
aging processes and hasten the development of biological-based
intervention strategies to extend the human health span. Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0 or Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-0325, telephone (202) 783-3238.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign for-profit and
non-profit organizations, public and private, such as universities,
colleges, research foundations, hospitals, laboratories, units of State
and local governments, and eligible agencies of the Federal Government.
Applications from domestic institutions may include international
components if the collaborative effort between domestic and foreign
investigators strengthen the research application.  Applications from
minority individuals and women are encouraged.

MECHANISM OF SUPPORT

The multidisciplinary, highly interactive approach outlined in this RFA
is intended to facilitate and enhance research progress toward
understanding complex problems in aging biology.  This RFA is a
one-time solicitation for research applications.  The total project
period for applications submitted in response to this RFA may not
exceed five years.  The anticipated award date for applications
submitted in response to this RFA is July 1, 1993.

The Genetic and Molecular Basis of Longevity research program will be
supported through the traditional research project grant (R01)
mechanism.  Applicants will be responsible for the planning, direction,
and execution of the proposed research projects.  Research applications
from collaborating Principal Investigators at different institutions
are highly encouraged if the combined expertise of the two research
laboratories will facilitate the research progress of both laboratories
and contribute to the overall research goals outlined in this RFA.

FUNDS AVAILABLE

The NIA will set aside a total of $2,000,000 for funding research
projects responsive to the Genetic and Molecular Basis of Longevity RFA
in FY 1993 and expects to make eight to ten grant awards.  Although
this research initiative is provided for in the plans of the NIA, the
award of research grants pursuant to this RFA is contingent upon the
availability of appropriated funds in FY 1993 and the receipt of a
sufficient number of responsive applications with high scientific
merit.

RESEARCH OBJECTIVES

Research with several model systems including yeast, nematodes,
drosophila, rats, mice, and cultured human cells has established that
longevity and senescence are, in part, under genetic control.  The
purposes of this RFA are to stimulate research on the fundamental
mechanisms of aging and senescence, to encourage the application of
results obtained from model systems to understanding human longevity,
and to develop intervention strategies to extend the human health span
based on increased knowledge of fundamental aging mechanisms.  The
interactive, multidisciplinary approach outlined in this RFA is
designed to focus the use of various model systems, human cells and
cell lines, molecular reagents, and state-of-the-art molecular biology
and biotechnology on this important area of aging biology.  The
development of sophisticated methods for molecular cloning, gene
amplification, targeted gene insertion and disruption, and the
production of germ-line transgenic organisms via molecular genetic
manipulation of embryos or embryonic stem cells have made such an
approach feasible.  Application of these powerful molecular approaches
to aging research will facilitate the identification of candidate LAG,
allow evaluation of their effects on longevity and health span in
transgenic model systems, and hasten the search for human homologs of
key LAGs.  It is anticipated that such an approach will facilitate and
optimize research progress and hasten the development of
biological-based intervention strategies designed to prevent or delay
human aging processes and thereby extend the human health span.

The major objectives of the Genetic and Molecular Basis of Longevity
RFA and research initiative are:

o  Development of molecular and animal resources to investigate the
molecular basis of longevity;
o  Identification of candidate LAGs in appropriate models of aging;
o  Evaluation of candidate LAG effects on longevity and senescence in
appropriate transgenic organisms;
o  Characterization of the regulation of LAG expression at the
molecular level;
o  Characterization of the biological functions of proteins encoded by
LAGs, and
o  Identification of human counterparts of key LAGs in cultured cells.

The development and application of several areas of molecular
technology to these problems in aging biology have been identified as
high priority including:

o  Development of suitable expression vectors and protocols for
introduction and stable expression of targeted gene transplacements and
the incorporation of multigenic DNA fragments in mouse embryonic stem
cells.

o  Development of suitable expression vectors and protocols to achieve
cell-specific expression of candidate transgenes in somatic cells of
young adult and aged mice.

o  Identification and characterization of age-specific promoters and
regulatory molecules that could be used to enhance the expression of
candidate genes in aged organisms.

o  Identification of inducible promoters that will drive the expression
of transgenes in aged and senescent animals.

The availability of additional animal models would aid in the
identification and evaluation of candidate LAGs.  For example, the
creation of long-lived strains of mice by selective breeding of highly
outbred founder populations and the genetic and molecular
characterization of these strains is an important aspect of this
research initiative.  In addition, the creation and maintenance of
transgenic mouse lines harboring key LAGs will provide another
important animal resource for this and future research initiatives to
define the genetic and molecular basis of longevity.

Several experimental strategies for the identification and evaluation
of candidate LAGs appear to be appropriate for this RFA.  These include
the evaluation of the effects of known genes believed to have the
characteristics of LAGs (for example, SOD, catalase, and LAG1) on
longevity and health span in transgenic organisms, genetic mapping of
candidate longevity loci in long-lived mouse strains, isolation and
characterization of key genes (regulatory and structural) that are
differentially expressed in animals subjected to caloric restriction
compared to ad libitum fed controls, and identification of human
homologs of LAGs using molecular probes isolated from other model
systems.  In addition, experiments to test the effect of candidate
genes on longevity and senescence in transgenic organisms (invertebrate
and vertebrate) is anticipated via targeted gene disruption and
targeted gene transplacement are encouraged.

The research topics listed above should not be interpreted as the only
experimental approaches to the identification of the genetic and
molecular bases of longevity and senescence. Additional innovative
approaches applicable to the research goals of this RFA are welcome and
encouraged.

SPECIAL REQUIREMENTS

Applicants are responsible for proposing research projects that will
advance the goals of the Genetic and Molecular Bases of Longevity
research initiative.  Applicants must have access to appropriate animal
and/or cell culture models for aging research and have the necessary
expertise in genetics, molecular biology, cell biology, or biochemistry
to carry out the proposed research projects.

LETTER OF INTENT

Prospective applicants are asked to submit a letter of intent by
October 1, 1992.  The letter of intent must include the number and
title of this RFA (AG-93-01), a descriptive title of the proposed
project, and the name, address, phone and FAX numbers of the Principal
Investigator and key co-investigators.  If the application will involve
collaborative or consortium arrangements, the participating
institutions must also be identified.  Although a letter of intent is
not binding and does not enter into the review of the subsequent
application, the letter is requested to provide an indication to the
NIA of the number and scope of applications to be reviewed.

Additional information related to the goals and scope of this RFA will
be provided to investigators who have submitted a letter of intent.
The letter of intent is to be addressed to:

Dr. Anna M. McCormick
Biology of Aging Program
National Institute on Aging
Gateway Building, Suite 2C231
Bethesda, MD  20892
Telephone:  (301) 496-6402
FAX:  (301) 402-0010

APPLICATION PROCEDURES

Applications are due November 13, 1992.  The research grant application
form PHS 398 (rev. 9/91) is to be used in applying for this grant.
These forms are available from most institutional grants and business
offices and from the Office of Grant Inquiries, Division of Research
Grants, National Institutes of Health, Room 449, Westwood Building,
5333 Westbard Avenue, Bethesda, MD  20892-4500.

REVIEW CONSIDERATIONS

Applications judged to be responsive to the RFA and competitive will be
evaluated for scientific and technical merit by an appropriate ad hoc
peer review group convened by the NIA Office of Scientific Review.  The
second level of review, which considers the priorities and special
needs of the NIA, will be conducted by the National Advisory Council on
Aging.

INQUIRIES

The program official welcomes the opportunity to clarify any issues or
questions from potential applicants.  Written and telephone inquiries
concerning the objectives and scope of the Genetic and Molecular Basis
of Longevity RFA, or whether a specific areas of research would be
considered by the NIA as responsive to this RFA are encouraged.

Direct inquires regarding programmatic issues to:

Dr. Anna M. McCormick
Chief, Biology Branch
Biology of Aging Program
National Institute on Aging
Gateway Building, Suite 2C231
Bethesda, MD  20892

Direct inquires regarding fiscal matters to:

Mr. Joseph Ellis
Grants Management Officer
Grants and Contracts Management Office
National Institute on Aging
Gateway Building, Suite 2N212
Bethesda, MD  20892
Telephone:  (301) 496-1472

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic assistance
No. 93.866.  Awards are made under the authorization of the Public
Health Service Act, Title IV, Part A (Public Law 99-158, 42 USC 241 and
285) and administered under PHS grants policies and Federal Regulations
42 CFR 52 and 45 CFR Part 74. This program is not subject to the
intergovernment review requirements of Executive Order 12372 or Health
Systems Agency review.

$$R2 END ************************************************************

$$R3 BEGIN CA/NR/92-27 FULL-TEXT ************************************

QUALITY OF LIFE ASSESSMENT IN SPECIAL POPULATIONS

NIH GUIDE, Volume 21, Number 33, September 11, 1992

RFA AVAILABLE:  CA/NR-92-27

P.T. 34; K.W. 0730070, 0414014, 0413001, 0414013, 0785035

National Cancer Institute
National Center for Nursing Research

Letter of Intent Receipt Date:  October 23, 1992
Application Receipt Date:  January 19, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The National Cancer Institute (NCI) and the National Center for Nursing
Research (NCNR) invite investigator-initiated grant applications (R01s)
to develop methods for assessing health-related quality of life (QOL)
or specific QOL dimensions in cancer patients from diverse
sociocultural backgrounds.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Quality of Life Assessment in Special Populations, is related to the
priority area of cancer.  Potential applicants may obtain a copy of
"Healthy People 2000" (Full Report:  Stock No. 017-001-00474-0 or
Summary Report:  Stock No. 017-001-00473-1) through the Superintendent
of Documents, Government Printing Office, Washington, DC 20402-9325,
telephone 202-783-3238.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic and foreign,  for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of state and local
governments, and eligible agencies of the Federal Government.
Applications from minority individuals and women are encouraged.

MECHANISM OF SUPPORT

This RFA will use the National Institutes of Health (NIH) individual
research grant (R01).  The applicant has sole responsibility for
planning, direction, and execution of the proposed project.  Total
project period for applications submitted in response to this RFA must
not exceed three years.

This RFA is a one-time solicitation.  Future unsolicited competitive
continuation applications will compete with all other
investigator-initiated research grant applications and be reviewed
according to the customary NIH peer review procedures.

FUNDS AVAILABLE

Total costs of $1,600,000 per year for three years will be committed to
specifically fund applications submitted in response to this RFA.  It
is anticipated that five to six awards will be made.  This funding
level is dependent upon the receipt of a sufficient number of
applications of high scientific merit.  Although this program is
provided for in the financial plans of the NCI and the NCNR, the awards
pursuant to this RFA are also contingent upon the availability of funds
for this purpose.

RESEARCH OBJECTIVES

This RFA fosters development of methods for assessing health-related
QOL in cancer patients from diverse sociocultural backgrounds.
Objectives include:  (1) development or adaptation of existing methods
for use in culturally diverse populations; (2) validation of methods in
the target population; and (3) pilot testing of methods in a clinical
trial in the target population.

For this RFA, special populations include Hispanic Americans, Black
Americans, low socioeconomic status groups, and persons with low
literacy skills.  Other smaller minority or ethnic groups such as
Native Americans, may be considered under defined circumstances.
Potential applicants are advised to contact NCI or NCRR program staff
if there are any questions regarding the consideration of a particular
research population.

Methods must focus on global health-related QOL or specific domains or
aspects of QOL, such as functional status, physical symptoms,
psychological function, and social function.  Methods should evaluate
within-person change over time.  When feasible, adaptation of existing
methodology for use in special populations is preferred.

General acceptability of the QOL assessment method must be evaluated in
patients from the target population. Psychometric validation must
include demonstration of reproducibility, construct validity, and
responsiveness. Applicability must be demonstrated by pilot testing in
a clinical research project.

STUDY POPULATIONS

For projects involving clinical research, the NIH requires applicants
to give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without documentation
will not be accepted for review.

LETTER OF INTENT

Each prospective applicant is asked to submit, by October 23, 1992, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, telephone/FAX numbers of the Principal
Investigator, the names of other key personnel and participating
institutions, and the number and title of the RFA in response to which
the application is being submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of a subsequent application, it contains
information that is helpful in planning for the review.  It allows NCI
and NCNR staff to estimate the potential review workload and to avoid
possible conflict of interest in the review.  The letter of intent is
to be sent to the Program Director named in INQUIRIES.

APPLICATION PROCEDURES

Applications must be received by January 19, 1993.  Application form
PHS 398 and information about application procedures may be obtained
from the NCI Program Director named in INQUIRIES.

REVIEW CONSIDERATIONS

Applications that are competitive and responsive to the RFA will be
evaluated for scientific and technical merit by an appropriate peer
review group according to specific review criteria.  A second level of
review will consider special needs and research priorities of the NCI
and the NCNR.

INQUIRIES

Written and telephone requests for the RFA and the opportunity to
clarify any issues or questions from potential applicants are welcome.
Direct requests for the RFA and inquiries regarding programmatic issues
to:

Susan G. Nayfield, M.D., M.Sc.
National Cancer Institute
Executive Plaza North, Suite 300
Bethesda, MD  20892
Telephone:  (301) 496-8541

Direct inquiries regarding fiscal matters to:

Mrs. Eileen M. Natoli
National Cancer Institute
Executive Plaza South, Suite 242
Bethesda, MD  20892
Telephone:  (301) 496-7800

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.399, Cancer Control Research, and 93.361, Nursing Research.
Awards are made under the authorization of the Public Health Service
Act, Title IV, Part A (Public Law 78-410, as amended by Public Law
99-158, 42 USC 241 and 285) and administered under PHS grants policies
and Federal Regulations 42 CFR 52 and 45 CFR Part 74.  This program is
not subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.

$$R3 END ************************************************************

                               ERRATUM

$$E1 BEGIN R1 19920828 APPEND RFA DK-93-03 BOTH ************************

CAREER DEVELOPMENT AWARDS FOR UNDERREPRESENTED MINORITY
CLINICIAN-INVESTIGATORS

NIH GUIDE, Volume 21, Number 33, September 11, 1992

RFA:  DK-93-03

P.T. 34, FF; K.W. 0785035, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases

The following paragraphs are to be added under the appropriate sections
to the Request for Applications DK-93-03 that was published in the NIH
Guide for Grants and Contracts, Vol. 21, No. 31, August 28, 1992.

ELIGIBILITY REQUIREMENTS

For the purposes of this announcement, underrepresented minority
investigators are individuals belonging to a particular racial or
ethnic group that has been determined by the grantee institution to be
underrepresented in biomedical or behavioral research.  Nationally,
individuals who have been found to be underrepresented in biomedical or
behavioral research include, but are not limited to, Black Americans,
Hispanic Americans, Native Americans, and Pacific Islanders.

MECHANISMS OF SUPPORT

Grant funds awarded under the CIA and the PSA mechanisms are for the
development of research training only and may not be used for the
support of clinical training or clinical services.  Such activities
must be supported from other funding sources.

INQUIRIES

Direct requests and inquiries regarding programmatic issues to:

Lois F. Lipsett, Ph.D.
Division of Diabetes, Endocrinology, and Metabolic Diseases
Telephone:  (301) 496-7433

$$E1 END ************************************************************

$$E2 BEGIN N1 19920828 APPEND NOTICE ***********************************

WORKSHOP ON MINIMIZING PAIN AND DISTRESS IN LABORATORY ANIMALS

NIH GUIDE, Volume 21, Number 33, September 11, 1992

P.T. 42; K.W. 0201011, 1014003

National Institutes of Health

The correct telephone number for inquiries regarding the Workshop on
Minimizing Pain and Distress in Laboratory Animals co-sponsored by the
National Institutes of Health, Vanderbilt University, and Meharry
Medical College, on December 3 - 4, 1992, is (615) 322-4030.  The
telephone number given in the NIH Guide for Grants and Contracts, Vol.
21, No. 31, August 28, 1992 was incorrect.

INQUIRIES

For information regarding future workshops, contact:

Ms. Roberta Sonneborn
Telephone:  (301) 496-7163
FAX:  (301) 402-2803

$$E2 END ************************************************************